The purpose of this study is testing the use of Enhanced-Butanol purified-Food Allergy Herbal
Formula-2 (E-B-FAHF-2) Chinese herbal therapy in combination with multi-food oral
immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to
foods be able to safely tolerate food allergens. Specifically in this protocol, the food
allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat.
Omalizumab is considered an investigational drug for the treatment of food allergies in
children and adults. Investigational means it has not been approved by the Food and Drug
Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition
of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness
(which is the ability to consume a food allergen and pass an oral food challenge after being
off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab +
herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely
ingest the foods they are allergic to.